NO2425815T3 - - Google Patents

Info

Publication number: NO2425815T3
Authority: NO; Norway

Application number

NO11191277A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-19

Filing date

2009-09-16

Publication date

2018-03-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41353867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2425815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-16 Application filed filed Critical

2018-03-24 Publication of NO2425815T3 publication Critical patent/NO2425815T3/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO11191277A 2008-09-19 2009-09-16 NO2425815T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9828008P	2008-09-19	2008-09-19
EP09792581.2A EP2328551B1 (en)	2008-09-19	2009-09-16	Stabilized pharmaceutical sub-micron suspensions and methods of forming same

Publications (1)

Publication Number	Publication Date
NO2425815T3 true NO2425815T3 (da)	2018-03-24

Family

ID=41353867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO11191277A NO2425815T3 (da)	2008-09-19	2009-09-16

Country Status (26)

Country	Link
US (3)	US20100076045A1 (da)
EP (2)	EP2425815B1 (da)
JP (3)	JP5739809B2 (da)
KR (1)	KR101682924B1 (da)
CN (2)	CN102176898A (da)
AR (2)	AR073597A1 (da)
AU (1)	AU2009293400B2 (da)
BR (1)	BRPI0919199B8 (da)
CA (1)	CA2736106C (da)
CL (1)	CL2009001856A1 (da)
CY (1)	CY1119740T1 (da)
DK (1)	DK2425815T3 (da)
ES (2)	ES2592503T3 (da)
HR (1)	HRP20180050T1 (da)
HU (1)	HUE037933T2 (da)
LT (1)	LT2425815T (da)
MX (1)	MX348204B (da)
NO (1)	NO2425815T3 (da)
PL (2)	PL2425815T3 (da)
PT (2)	PT2425815T (da)
RU (1)	RU2521258C2 (da)
SI (1)	SI2425815T1 (da)
TW (1)	TWI580441B (da)
UY (1)	UY32095A (da)
WO (1)	WO2010033528A1 (da)
ZA (1)	ZA201101398B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070202186A1 (en)	2006-02-22	2007-08-30	Iscience Interventional Corporation	Apparatus and formulations for suprachoroidal drug delivery
US20100234469A1 (en) *	2009-03-12	2010-09-16	Medichem, S.A.	New Crystals Of A Benzoylbenzeneacetamide Derivative
JP5996544B2 (ja)	2010-10-15	2016-09-21	クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅＢｉｏｍｅｄｉｃａｌＩｎｃｏｒｐｏｒａｔｅｄ	眼球アクセス用装置
WO2012077038A1 (en) *	2010-12-06	2012-06-14	Degama Berrier Ltd.	Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
CN111700879A (zh) *	2012-05-03	2020-09-25	卡拉制药公司	显示提高的粘膜转移的药物纳米粒子
JP6360039B2 (ja)	2012-05-03	2018-07-18	カラファーマシューティカルズインコーポレイテッド	複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en)	2012-05-03	2026-02-10	Alcon Inc	Pharmaceutical nanoparticles showing improved mucosal transport
EP2934484A1 (en) *	2012-12-19	2015-10-28	Kashiv Pharma, LLC	Supersaturated stabilized nanoparticles for poorly soluble drugs
EP2956138B1 (en)	2013-02-15	2022-06-22	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es)	2013-02-20	2019-10-21	Kala Pharmaceuticals Inc	Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
BR112015027762A2 (pt)	2013-05-03	2017-08-29	Clearside Biomedical Inc	Aparelho e métodos para injeção ocular
US9458169B2 (en)	2013-11-01	2016-10-04	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
WO2016036588A1 (en) *	2014-09-03	2016-03-10	Merck Sharp & Dohme Corp.	Pharmaceutical suspensions containing etoricoxib
EP3452165A1 (en)	2016-05-02	2019-03-13	Clearside Biomedical, Inc.	Systems and methods for ocular drug delivery
IL305537B2 (en)	2016-08-12	2025-02-01	Clearside Biomedical Inc	Devices and methods for adjusting the insertion depth of a needle for administering a drug
EP3509423A4 (en)	2016-09-08	2020-05-13	Kala Pharmaceuticals, Inc.	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en)	2016-09-08	2020-08-13	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en)	2016-09-08	2019-07-02	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
CA3037174A1 (en) *	2016-09-16	2018-03-22	Kala Pharmaceuticals, Inc.	Particles, compositions, and methods for ophthalmic and/or other applications
CA3136814A1 (en)	2019-04-16	2020-10-22	Clearside Biomedical, Inc.	Injectable triamcinolone formulations
WO2025183017A1 (ja) *	2024-02-26	2025-09-04	大塚製薬株式会社	Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5466680A (en) *	1992-03-26	1995-11-14	Cytologics, Inc.	Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
ES2079994B1 (es) *	1992-10-07	1996-08-01	Cusi Lab	Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5298262A (en) *	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) *	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
WO1995005803A1 (en) *	1993-08-20	1995-03-02	Alcon Laboratories, Inc.	Topical ophthalmic pharmaceutical vehicles
US5718919A (en) *	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
US6969529B2 (en) *	2000-09-21	2005-11-29	Elan Pharma International Ltd.	Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) *	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) *	2000-09-21	2002-04-23	Elan Pharma International Ltd.	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
JP4763957B2 (ja) *	2000-05-10	2011-08-31	オバン・エナジー・リミテッド	メディアミリング
PE20020146A1 (es) *	2000-07-13	2002-03-31	Upjohn Co	Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2219910C2 (ru) *	2002-01-08	2003-12-27	Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН	Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты)
US7138468B2 (en) *	2002-03-27	2006-11-21	University Of Southern Mississippi	Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT
EP2283864A1 (en) *	2002-07-16	2011-02-16	Elan Pharma International Ltd.	Liquid dosage compositions fo stable nanoparticulate active agents
KR20050096936A (ko) *	2003-01-15	2005-10-06	다우 글로벌 테크놀로지스 인크.	차가운 표면 위에서 동결시켜 수득한 약물 입자
US20040235892A1 (en) *	2003-05-22	2004-11-25	Yujia Dai	Indazole and benzisoxazole kinase inhibitors
RU2006113593A (ru) *	2003-09-23	2006-08-27	Алькон, Инк. (Ch)	Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US20060141049A1 (en) *	2003-11-12	2006-06-29	Allergan, Inc.	Triamcinolone compositions for intravitreal administration to treat ocular conditions
EP1713514B1 (en) *	2004-01-28	2021-11-24	Johns Hopkins University	Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006043172A1 (en) *	2004-10-19	2006-04-27	Pfizer Inc.	Pharmaceutical compositions and methods for sub-tenon delivery
WO2006062875A1 (en) *	2004-12-08	2006-06-15	Merck & Co., Inc.	Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TW200640443A (en) *	2005-02-23	2006-12-01	Alcon Inc	Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
AU2006235487B2 (en) *	2005-04-12	2011-12-22	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
EP1874267A1 (en) *	2005-04-13	2008-01-09	Pfizer Products Inc.	Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US7893040B2 (en) *	2005-07-22	2011-02-22	Oculis Ehf	Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5112669B2 (ja) *	2005-09-30	2013-01-09	富山化学工業株式会社	難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070149480A1 (en) *	2005-12-23	2007-06-28	Alcon, Inc.	PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070196350A1 (en) *	2006-02-22	2007-08-23	Bartels Stephen P	Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

2009
- 2009-09-03 TW TW098129672A patent/TWI580441B/zh active
- 2009-09-07 UY UY0001032095A patent/UY32095A/es not_active Application Discontinuation
- 2009-09-15 CL CL2009001856A patent/CL2009001856A1/es unknown
- 2009-09-16 PT PT111912770T patent/PT2425815T/pt unknown
- 2009-09-16 AU AU2009293400A patent/AU2009293400B2/en active Active
- 2009-09-16 CA CA2736106A patent/CA2736106C/en active Active
- 2009-09-16 ES ES09792581.2T patent/ES2592503T3/es active Active
- 2009-09-16 PL PL11191277T patent/PL2425815T3/pl unknown
- 2009-09-16 DK DK11191277.0T patent/DK2425815T3/da active
- 2009-09-16 CN CN2009801371097A patent/CN102176898A/zh active Pending
- 2009-09-16 WO PCT/US2009/057065 patent/WO2010033528A1/en not_active Ceased
- 2009-09-16 BR BRPI0919199A patent/BRPI0919199B8/pt active IP Right Grant
- 2009-09-16 SI SI200931783T patent/SI2425815T1/en unknown
- 2009-09-16 ES ES11191277.0T patent/ES2657455T3/es active Active
- 2009-09-16 EP EP11191277.0A patent/EP2425815B1/en active Active
- 2009-09-16 MX MX2011002494A patent/MX348204B/es active IP Right Grant
- 2009-09-16 PT PT97925812T patent/PT2328551T/pt unknown
- 2009-09-16 AR ARP090103553A patent/AR073597A1/es not_active Application Discontinuation
- 2009-09-16 US US12/560,509 patent/US20100076045A1/en not_active Abandoned
- 2009-09-16 JP JP2011527909A patent/JP5739809B2/ja active Active
- 2009-09-16 KR KR1020117008617A patent/KR101682924B1/ko active Active
- 2009-09-16 EP EP09792581.2A patent/EP2328551B1/en active Active
- 2009-09-16 CN CN201510086562.7A patent/CN104688682A/zh active Pending
- 2009-09-16 HU HUE11191277A patent/HUE037933T2/hu unknown
- 2009-09-16 RU RU2011115211/15A patent/RU2521258C2/ru active
- 2009-09-16 LT LTEP11191277.0T patent/LT2425815T/lt unknown
- 2009-09-16 NO NO11191277A patent/NO2425815T3/no unknown
- 2009-09-16 PL PL09792581T patent/PL2328551T3/pl unknown
2011
- 2011-02-22 ZA ZA2011/01398A patent/ZA201101398B/en unknown
2014
- 2014-06-11 US US14/302,122 patent/US20140294970A1/en not_active Abandoned
- 2014-12-11 JP JP2014250576A patent/JP2015052020A/ja not_active Withdrawn
2016
- 2016-12-02 JP JP2016234682A patent/JP2017043637A/ja not_active Withdrawn
2017
- 2017-04-21 US US15/493,232 patent/US20170216228A1/en not_active Abandoned
2018
- 2018-01-05 CY CY20181100015T patent/CY1119740T1/el unknown
- 2018-01-10 HR HRP20180050TT patent/HRP20180050T1/hr unknown
2022
- 2022-01-14 AR ARP220100069A patent/AR124648A2/es unknown

Also Published As

Publication number	Publication date
US20100076045A1 (en)	2010-03-25
WO2010033528A1 (en)	2010-03-25
US20170216228A1 (en)	2017-08-03
CN102176898A (zh)	2011-09-07
ZA201101398B (en)	2012-04-25
ES2592503T3 (es)	2016-11-30
ES2657455T3 (es)	2018-03-05
UY32095A (es)	2010-01-29
CN104688682A (zh)	2015-06-10
BRPI0919199A2 (pt)	2015-12-15
HUE037933T2 (hu)	2018-09-28
AR073597A1 (es)	2010-11-17
JP5739809B2 (ja)	2015-06-24
EP2425815A1 (en)	2012-03-07
CL2009001856A1 (es)	2010-12-31
EP2425815B1 (en)	2017-10-25
SI2425815T1 (en)	2018-02-28
EP2328551B1 (en)	2016-06-15
BRPI0919199B1 (pt)	2020-10-27
KR20110054055A (ko)	2011-05-24
RU2521258C2 (ru)	2014-06-27
CA2736106C (en)	2016-08-16
TW201014612A (en)	2010-04-16
AR124648A2 (es)	2023-04-19
HRP20180050T1 (hr)	2018-02-09
AU2009293400A1 (en)	2010-03-25
JP2015052020A (ja)	2015-03-19
LT2425815T (lt)	2018-01-25
JP2012503003A (ja)	2012-02-02
TWI580441B (zh)	2017-05-01
CA2736106A1 (en)	2010-03-25
MX348204B (es)	2017-05-30
DK2425815T3 (da)	2018-01-29
EP2328551A1 (en)	2011-06-08
MX2011002494A (es)	2011-04-07
BRPI0919199B8 (pt)	2021-05-25
RU2011115211A (ru)	2012-10-27
HK1152258A1 (zh)	2012-02-24
JP2017043637A (ja)	2017-03-02
AU2009293400B2 (en)	2015-05-07
PL2425815T3 (pl)	2018-03-30
PT2328551T (pt)	2016-09-22
PT2425815T (pt)	2018-01-31
PL2328551T3 (pl)	2017-04-28
US20140294970A1 (en)	2014-10-02
CY1119740T1 (el)	2018-09-05
KR101682924B1 (ko)	2016-12-06

Publication	Publication Date	Title
BR112016019572A2 (da)	2017-08-15
BRPI0909040A2 (da)	2017-09-19
BRPI0917573A2 (da)	2017-07-11
BRPI0908549B8 (da)	2021-06-08
BRPI0918697A2 (da)	2017-08-29
BRPI0917525A2 (da)	2017-07-04
BRPI0920750A2 (da)	2016-02-02
BRPI0919470A2 (da)	2017-08-22
BRPI0907698A2 (da)	2017-08-22
BRPI0917618A8 (da)	2019-09-10
BRPI0922455A2 (da)	2021-12-28
BRPI0923734A2 (da)	2017-07-11
BRPI0912727A2 (da)	2017-08-29
BRPI0922669A2 (da)	2017-07-11
BRPI0908285A2 (da)	2017-08-29
BRPI0910485A2 (da)	2017-08-29
BRPI0914750A2 (da)	2017-08-15
BRPI0919811A2 (da)	2017-08-29
BRPI0915616A2 (da)	2016-02-02
BRPI0908120A2 (da)	2017-08-22
BRPI0912462A2 (da)	2016-02-02
BRPI0904541A8 (da)	2010-09-21
BRPI0920914A2 (da)	2017-07-11
BRPI0922550A2 (da)	2016-02-02
BRPI0916284A2 (da)	2017-08-08